Novel PARP Inhibitor Suppresses Cervical Tumors by Activating Immune Signaling in Mice
The novel PARP inhibitor No. 123 suppresses cervical cancer progression in preclinical models through a dual mechanism of direct cytotoxicity ...
The novel PARP inhibitor No. 123 suppresses cervical cancer progression in preclinical models through a dual mechanism of direct cytotoxicity ...
Targeting PARP and SHP2 pathways simultaneously overcame therapy resistance and slowed tumor growth in preclinical models of advanced breast cancer.
Radiometal-labelled olaparib derivatives fail to cross cell membranes, rendering them unsuitable for targeted radionuclide therapy or PET imaging of intranuclear ...
A retrospective study of 125 advanced sarcoma patients found molecular tumor board recommendations led to treatment in 32.8 percent, with ...
A genome-wide CRISPR screen identifies UGCG-driven sphingolipid metabolism and protective autophagy as drivers of Niraparib resistance in ovarian cancer.
Updated Phase 3 DUO-E trial results presented at ESMO 2026 show that durvalumab plus olaparib after chemotherapy achieved a median ...
New research shows that triple-negative breast cancer cells rely on shared DNA damage tolerance enzymes such as POLζ and CHK1 ...
Researchers combined anti-PD-L1 immunotherapy with the PARP inhibitor Olaparib to trigger ferroptosis in liver cancer and used the SLC7A11-targeted PET ...
A phase Ib/II trial in China found that the oral PARP inhibitor HTMC0435 combined with temozolomide produced a manageable safety ...
A Phase 1 trial found that combining the ATR inhibitor ceralasertib with the PARP inhibitor olaparib was generally well tolerated ...
A real-world study of 214 patients finds that adding Bevacizumab to Olaparib maintenance therapy significantly improves overall survival only in ...
We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.
Bioengineer.org © Copyright 2023 All Rights Reserved.
Bioengineer.org © Copyright 2023 All Rights Reserved.